A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

Background: Ample evidence indicates the efficacy of serotonin type 3 (5-HT3) receptor antagonists in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Mirtazapine is an atypical antidepressant with a well-known 5-HT3 receptor antagonist property. This study, ther...

Full description

Bibliographic Details
Main Authors: Ahmadimoghaddam, D. (Author), Khalilian, A. (Author), Mehrpooya, M. (Author), Mohammadi, Y. (Author), Saki, S. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2021
Subjects:
5-hydroxytryptamine
Diarrhea
Irritable bowel syndrome
Mirtazapine
Online Access:View Fulltext in Publisher

Similar Items

Similar Items